2026-01-15 - Analysis Report
**English Report**

**Company Overview**
Regeneron Pharmaceuticals Inc - a biotechnology company.

**Return Rate Comparison**

* Cumulative return of review stock (REGN) = **28.95%**
* Cumulative return of comparison stock (S&P 500, VOO) = **92.89%**
* Rate of review stock = 28.95%
* Rate of comparison stock (VOO) = 92.89%
* Rate vs: 64.20%
* Divergence: -64.20

**Alpha, Beta Analysis | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |**

|------------|------|------|-------|------|-------|
| 2016-2018  | -14.0% | 22.4% | -18.0% | 1.2 | 39.6B |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B |

**Recent Stock Price Fluctuations**

* Close = $754.14
* Last-market change = -0.63%
* 5-day SMA = $775.72
* 20-day SMA = $773.97
* 60-day SMA = $715.82

**RSI, PPO Index Indicators and Delta Previous Relative Divergence**

* Market Risk Indicator (MRI) = 0.70
* RSI = 38.96
* PPO = -0.73
* Recent relative divergence change = -2.90%
* 7-day Rank change = 0
* 7-day Dynamic Expected Return change = 0.00%
* Expected Return (%) = -39.30%

**Recent News & Significant Events**

* Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
* Regeneron Pharmaceuticals Stock (REGN) Opinions on Dupixent Success and Pipeline Developments - Quiver Quantitative
* Why Regeneron (REGN) Stock Is Trading Up Today
* Regeneron Stock: The Turnaround Is Gaining Steam
* Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside
* Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Analyst Buy Upgrades

**Analyst Opinions**

**Analyst Consensus:**
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 826.04 / 1057.00 / 630.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|---:|------: |
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

**Financial Information**

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

**Comprehensive Analysis**

Regeneron Pharmaceuticals Inc. has shown a strong return performance, outperforming the S&P 500 (VOO) with a cumulative return of **28.95%** compared to **92.89%**. 

However, the recent stock price fluctuations indicate a slight decline with a 20-day SMA and 60-day SMA below the current stock price. The RSI indicates that the stock may be oversold, and the PPO suggests a bearish trend.

Despite the recent downturn, the company has shown a strong earnings growth with a mean EPS of **11.43** in the past two quarters. The revenue and profitability have consistently increased, with a mean profit margin of **85.63%**.

The market risk indicator (MRI) is 0.70, indicating a medium investment risk, and the expected return is **-39.30%**, suggesting a significant decline in long-term investment returns. Therefore, investors should carefully evaluate the company's performance and assess the potential risks before making a decision.

Analysts have offered mixed opinions, with a mean rating of 1.69, indicating a buy recommendation. The target price is predicted to be around $826.04.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.